Vical: Cutbacks, Refocus Aim to Tackle Infectious Diseases
In a wagon-circling move typical after Phase III setbacks such as befell Vical Inc.'s compound for metastatic melanoma earlier this month, the company said it will cut its work force by about 39 percent, or 47 employees, leaving 74 still aboard, as the Allovectin project is abandoned and efforts turn to infectious-disease vaccine programs.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST